Ingen appoints director of r&d
Aims to increase sales of in vitro diagnostic (IVD) kits
Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.
‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'
Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Personal Protection
Gas safety in smaller pharmaceutical facilities
Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Manufacturing
Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution
This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
Research & Development
EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health
The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications